Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Cytokinetics' hopes of resurrecting cardiac myosin activator omecamtiv mecarbil have suffered another setback, after the drug failed to show a benefit in a phase 3 heart failure study.

Starr, who is Black, said she told the care team about research showing that the devices, which measure oxygen levels in the blood, may not work as well on people with darker skin and potentially ...

Besides stars, the United States Navy uses quasars as beacons. Quasars are distant galaxies with supermassive black holes, surrounded by ... X-Ray Flashes from a Nearby Supermassive Black Hole ...

RBC Capital Mkts has recently initiated Cytokinetics, Inc. (CYTK) stock to Outperform rating, as announced on November 8, 2024, according to Finviz. Earlier, on August 13, 2024, Goldman had reduced ...

After hours: January 17 at 6:11:16 PM EST ...

Aficamten is under clinical development by Cytokinetics and currently in Pre-Registration for Hypertrophic Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Hypertrophic ...

Happy January Music Monday and MLK Day here at Good Black News! It’s your friend and selector, your sonic chauffeur, your groove conductor, Marlon, back again. I’m delighted to offer up this first of ...